Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease.

about

Skin globotriaosylceramide 3 deposits are specific to Fabry disease with classical mutations and associated with small fibre neuropathy.

P2860

Q33866320-48E97F76-BA4C-4FF4-A8C4-191AD73AAD41

P2860

Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease.

Item

http://www.wikidata.org/entity/Q36193984

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease.

@ast

Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease.

@en

type

Item

label

Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease.

@ast

Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease.

@en

prefLabel

Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease.

@ast

Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease.

@en

P1476

Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease.

@en

P2093

Christoph Wanner

http://www.w3.org/2001/XMLSchema#string

Claudia Sommer

http://www.w3.org/2001/XMLSchema#string

Daniela Kramer

http://www.w3.org/2001/XMLSchema#string

Frank Weidemann

http://www.w3.org/2001/XMLSchema#string

Waldemar Kafke

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg

A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies

The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology.

A modified score to identify and discriminate neuropathic pain: a study on the German version of the Neuropathic Pain Symptom Inventory (NPSI).

Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy.

Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation.

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy

Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.

Agalsidase benefits renal histology in young patients with Fabry disease.

Increased arterial diameters in the posterior cerebral circulation in men with Fabry disease.

P304

e0166484

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0166484

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nurcan Üçeyler

Nils Schröter

P577

2016-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27851774

http://www.w3.org/2001/XMLSchema#string

P932

5112934

http://www.w3.org/2001/XMLSchema#string

Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease.

about

P2860

P2860

Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932